My project at LBI for Network Medicine: Testing the therapeutic utility of AutoCore in rare AI/AIF diseases.

I fetched raw bulk RNA-Seq data of different rare disease including:

Systemic lupus erythematosus (SLE), Inflammatory bowel disease (IBD) Rheumatoid arthritis (RA), Multiple sclerosis (MS), Type 1 diabetes (T1D), Sjögren’s syndrome, Graves disease, Myositis, Psoriatic arthritis, Psoriasis, Systemic sclerosis.


Microchimerism in Autoimmune Diseases in women

endotype

custom gene set


No data for MCTD

For IBD, fist I ran the analysis for the whole dataset based on the treatment of Infliximab and Vedalizimab (comparison: respondent vs. non-respondent) but it was too chaotic and the PCA was not good at all. Then I deparated based on Diagnosis, whether they are UC or CD. SO it would be in Infiliximab treated CD group, Infliximab treated UC and ...
